利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.038 秒)

    SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION
    2.
    发明申请
    SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION 失效
    作为A-beta蛋白质生产的抑制剂的SUCCINOYLAMINO LACTAMS

    公开(公告)号：US20080293692A1

    公开(公告)日：2008-11-27

    申请号：US11950399

    申请日：2007-12-04

    申请人： Richard E. Olson ,  Thomas P. Maduskuie ,  Lorin Andrew Thompson

    发明人： Richard E. Olson ,  Thomas P. Maduskuie ,  Lorin Andrew Thompson

    IPC分类号： A61K31/55 ,  C07D223/10 ,  C07D401/06 ,  A61P25/00 ,  A61K31/551 ,  C07D243/12

    CPC分类号： C07D401/06 ,  C07D223/12 ,  C07D243/24 ,  C07D401/10 ,  C07D405/12

    摘要： This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译： 本发明涉及具有药物和生物影响性质的新型内酰胺，其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工，更具体地，抑制Aβ肽的产生，从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，例如阿尔茨海默病和唐氏综合征。

    Succinoylamino lactams as inhibitors of a-β protein production
    4.
    发明授权
    Succinoylamino lactams as inhibitors of a-β protein production 失效
    琥珀酰氨基内酰胺作为α-β蛋白生产的抑制剂

    公开(公告)号：US07507815B2

    公开(公告)日：2009-03-24

    申请号：US11950399

    申请日：2007-12-04

    申请人： Richard E. Olson ,  Thomas P. Maduskuie ,  Lorin Andrew Thompson

    发明人： Richard E. Olson ,  Thomas P. Maduskuie ,  Lorin Andrew Thompson

    IPC分类号： C07D243/24

    CPC分类号： C07D401/06 ,  C07D223/12 ,  C07D243/24 ,  C07D401/10 ,  C07D405/12

    摘要： This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译： 本发明涉及具有药物和生物影响性质的新型内酰胺，其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工，更具体地，抑制Aβ肽的产生，从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，例如阿尔茨海默病和唐氏综合征。

    Succinoylamino lactams as inhibitors of a&bgr; protein
    5.
    发明授权
    Succinoylamino lactams as inhibitors of a&bgr; protein 有权
    琥珀酰氨基内酰胺作为abeta蛋白的抑制剂

    公开(公告)号：US06794381B1

    公开(公告)日：2004-09-21

    申请号：US09506360

    申请日：2000-02-17

    申请人： Richard E. Olson ,  Thomas P. Maduskuie ,  Lorin Andrew Thompson

    发明人： Richard E. Olson ,  Thomas P. Maduskuie ,  Lorin Andrew Thompson

    IPC分类号： C07D22300

    CPC分类号： C07D401/06 ,  C07D223/12 ,  C07D243/24 ,  C07D401/10 ,  C07D405/12

    摘要： This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译： 本发明涉及具有药物和生物影响性质的新型内酰胺，其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工，更具体地，抑制Aβ肽的产生，从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，例如阿尔茨海默病和唐氏综合征。

    Succinoylamino lactams as inhibitors of Aβ protein production
    6.
    发明授权
    Succinoylamino lactams as inhibitors of Aβ protein production 有权
    琥珀酰氨基内酰胺作为Abeta蛋白生产的抑制剂

    公开(公告)号：US07304055B2

    公开(公告)日：2007-12-04

    申请号：US11492593

    申请日：2006-07-25

    申请人： Richard E. Olson ,  Thomas P. Maduskuie ,  Lorin Andrew Thompson

    发明人： Richard E. Olson ,  Thomas P. Maduskuie ,  Lorin Andrew Thompson

    IPC分类号： C07D243/24 ,  A61K31/55 ,  A61P25/28

    CPC分类号： C07D223/12 ,  C07D243/24 ,  C07D401/06 ,  C07D401/10 ,  C07D405/12

    摘要： This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译： 本发明涉及具有药物和生物影响性质的新型内酰胺，其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工，更具体地，抑制Aβ肽的产生，从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地，本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病，例如阿尔茨海默病和唐氏综合征。

    Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
    7.
    发明授权
    Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases 有权
    尿嘧啶衍生物作为TNF-α转换酶（TACE）和基质金属蛋白酶的抑制剂

    公开(公告)号：US07101883B2

    公开(公告)日：2006-09-05

    申请号：US10389529

    申请日：2003-03-14

    申请人： Thomas P. Maduskuie

    发明人： Thomas P. Maduskuie

    IPC分类号： C07D239/02 ,  A01N43/58 ,  A61K31/50

    CPC分类号： C07D239/545 ,  C07D239/69 ,  C07D401/12

    摘要： The present application describes novel uracil derivatives of formula I: A-W-U-X-Y-Z-Ua-Xa-Ya-ZaI or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, W, U, X, Y, Z, Ua, Xa, Ya, and Za are defined in the present specification, which are useful as inhibitors of TNF-α converting enzyme (TACE), matrix metalloproteinases (MMP), aggrecanase or a combination thereof.

    摘要翻译： 本申请描述了式I的新型尿嘧啶衍生物：<？in-line-formula description =“In-line Formulas”end =“lead”？> AWUXYZU 或其药学上可接受的盐或其药学上可接受的盐或其药学上可接受的盐或其药学上可接受的盐，或其药学上可接受的盐或 其前体药物形式，其中A，W，U，X，Y，Z，U，A，X， 在本说明书中定义，它们可用作TNF-α转化酶（TACE），基质金属蛋白酶（MMP），聚蛋白聚糖蛋白聚糖酶或其组合的抑制剂。